Ablynx NV raised €31.5 million (US$41 million) in a private placement, boosting cash reserves to around €90 million and allowing the company to progress development of its next-generation rheumatoid arthritis (RA) product ALX-0061 into Phase IIb, while negotiating with potential partners.